Pharma-Bio Serv Reports Strong Net Income Growth and Revenue Rebound in Q2
PBSV sits 81% above its 52-week low of $0.313.
Summary
Pharma-Bio Serv announced a strong increase in net income and a rebound in revenue for Q2 2026, driven by cost savings, despite continued negative operating cash flow and a large uncollected legal judgment.
Key Events · Earnings and Guidance · PBSV
-
Significant Net Income Growth
Net income for the three months ended April 30, 2026, increased by 144.3% to $232,986, and for the six months, it rose by 155.9% to $265,846, compared to the same periods last year.
-
Revenue Rebound
Total revenues for the three months ended April 30, 2026, increased by 11.8% to $2.7 million, partially offsetting a modest 2.2% increase for the six-month period.
-
Continued Negative Operating Cash Flow
The company reported net cash used in operating activities of $(755,450) for the six months ended April 30, 2026, indicating ongoing cash burn from core operations.
-
Uncollected Legal Judgment
A $6.7 million judgment against Romark Global Pharma remains uncollected, with the company unable to identify assets for collection, representing a substantial financial overhang.
Analysis · PBSV · Trade & Services
Pharma-Bio Serv reported a significant turnaround in net income for the second quarter and first half of fiscal year 2026, alongside a rebound in quarterly revenue. This operational improvement is a positive development. However, the company continues to experience negative cash flow from operations, and its cash and cash equivalents have decreased. A substantial $6.7 million legal judgment remains uncollected, posing a significant financial risk relative to the company's market capitalization. Additionally, the expiration of a key Puerto Rico tax exemption in October 2024, with no update on its extension, introduces future uncertainty regarding tax liabilities.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.1% of the 1692 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBSV was trading at $0.57 on OTC in the Trade & Services sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.31 to $1.36. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.